Sanofi
Avatud
53.02 -0.43
Ülevaade
Aktsiahinna muutus
24h
Min
52.97
Max
53.52
Sissetulek | 1.7B 2.8B |
|---|---|
Müük | 2.8B 14B |
P/E Sektori keskmine | 30.71 104.138 |
Aktsiakasum | 2.25 |
Kasumimarginaal | 19.884 |
EBITDA | 2.2B 4.2B |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +22.02 upside |
Turukapital | 136B |
|---|---|
Eelmine avamishind | 53.45 |
Eelmine sulgemishind | 53.02 |
Tehniline skoor
By Trading Central
Kindlus
Weak Bearish Evidence
Sanofi Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Sanofi Prognoos
Hinnasiht
By TipRanks
22.02% tõus
12 kuu keskmine prognoos
Keskmine 65 USD 22.02%
Kõrge 67 USD
Madal 63 USD
Põhineb 3 Wall Streeti analüütiku instrumendi Sanofi 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Sanofi
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
